Pune Scientists Develop Dual Gene-Silencing Nanocarrier for Targeted Breast Cancer Therapy
Key Insights
Scientists from Agharkar Research Institute (search), Pune, have developed a biodegradable nanocarrier platform that simultaneously silences two critical anti-apoptotic genes, MCL-1 and Survivin (search), in breast cancer (search) cells.
The innovative system uses mesoporous silica nanoparticles (search) functionalized with MUC1 (search)-specific aptamers to achieve precise tumor targeting while minimizing systemic toxicity.
In vivo studies in SCID mice demonstrated effective tumor accumulation, robust gene knockdown, increased apoptosis, and substantial tumor growth inhibition with minimal side effects.
Scientists from the Agharkar Research Institute (search) (ARI) in Pune have developed a breakthrough biodegradable nanocarrier platform that simultaneously targets two critical cancer (search) survival genes, offering new hope for more effective and safer breast cancer (search) treatment. The research, recently published in Advanced Healthcare Materials, demonstrates how precision nanomedicine can directly silence disease-driving genes while minimizing systemic toxicity.
Innovative Dual Gene-Silencing Strategy
The research team, consisting of Niladri Haldar, Rajkumar Samanta, Surajit Patra, Devyani Sengar, Sachin Jadhav, and Virendra Gajbhiye from the Nanobioscience Group, engineered a sophisticated nanocarrier that simultaneously delivers small interfering RNA (siRNA) molecules against two critical anti-apoptotic genes: MCL-1 and Survivin (search). Both genes are known to promote tumor survival and resistance to therapy, making them prime targets for cancer (search) treatment.
The system is built on biodegradable mesoporous silica nanoparticles (search), which are well-established for their high loading capacity and tunable surface chemistry. By functionalizing the nanocarrier with a protamine biopolymer and an MUC1 (search)-specific aptamer, the researchers achieved precise tumor targeting by leveraging the overexpression of MUC1 receptors on breast cancer (search) cells.
Enhanced Targeting and Controlled Release
This targeting strategy significantly enhances cellular uptake while reducing off-target effects, addressing a key limitation in conventional therapies. Once inside the tumor microenvironment, the glutathione-responsive design triggers controlled release of the therapeutic payload, ensuring efficient intracellular delivery and activity.
The MUC1 (search)-targeted silica nanocarrier (MPPM) represents a convergence of targeted delivery, stimuli-responsive release, and combinatorial gene silencing integrated into a single biodegradable platform.
Promising Preclinical Results
Biological evaluations in MCF-7 breast cancer (search) models demonstrated robust gene knockdown, resulting in increased apoptosis and substantial tumor growth inhibition. The in vivo studies in Severe Combined Immunodeficiency (SCID) mice showed particularly encouraging results, with the nanocarrier accumulating effectively at tumor sites while exhibiting minimal systemic toxicity, as evidenced by favorable histological outcomes.
These findings align with growing evidence that aptamer-guided nanocarriers can significantly improve tumor specificity and therapeutic efficacy, representing a major advancement over traditional chemotherapy approaches.
Implications for Precision Oncology
The research provides new insights into targeted gene silencing of key survival pathways in breast cancer (search), enabling efficient tumor targeting and suppression. This work highlights how advances in cancer (search) nanomedicine are increasingly shifting toward precision strategies that directly silence disease-driving genes while minimizing systemic toxicity.
The study offers a promising strategy for developing more effective and safer nanomedicine-based therapies and provides a compelling framework for next-generation RNAi-based cancer (search) therapies. Such approaches could play a critical role in advancing precision oncology, offering more effective and safer alternatives to traditional chemotherapy.
The research was conducted by scientists from the Agharkar Research Institute (search), an autonomous institute under the Department of Science and Technology (DST), Government of India, demonstrating India's growing contribution to cutting-edge cancer (search) research and nanomedicine development.